CD274 and non-small cell lung carcinoma: CPIs have revolutionized the treatment of NSCLC, and most patients with newly diagnosed advanced NSCLC are indicated for treatment with PD-1 or PD-L1 antibodies, either as monotherapy or in combination (149, 150).